<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452607</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-1005-101</org_study_id>
    <nct_id>NCT01452607</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Pharmacokinetics of SPI-1005</brief_title>
  <official_title>A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sound Pharmaceuticals, Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sound Pharmaceuticals, Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine the safety, tolerability, and pharmacokinetics of SPI-1005 capsules in
      healthy adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 month</time_frame>
    <description>The primary objective of this study was to evaluate the safety and tolerability of SPI-1005 (ebselen) in healthy subjects. Incidence and severity of Adverse Events were determined in all treatment and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of SPI-1005 and its major metabolites in healthy subjects</measure>
    <time_frame>24 hours</time_frame>
    <description>Evaluate the single dose pharmacokinetic profile of SPI-1005 in healthy subjects including Tmax, Cmax, of the parent compound and major metabolites.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hearing Loss</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lowest Dose Evaluated, 200mg Ebselen Total, Delivered as a Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2x Lowest Dose Evaluated, 400mg Ebselen Total, Delivered as a Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4x Lowest Dose Evaluated, 800mg Ebselen Total, Delivered as a Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8x Lowest Dose Evaluated, 1600mg Ebselen Total, Delivered as a Single Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SPI-1000 Capsule 0 mg Ebselen Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo Capsule, 0mg Ebselen Total, Delivered as a Single Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPI-1005</intervention_name>
    <description>200 mg Ebselen oral capsules (SPI-1005), single dose</description>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x1</arm_group_label>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x2</arm_group_label>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x4</arm_group_label>
    <arm_group_label>SPI-1005 Capsule 200mg Ebselen x8</arm_group_label>
    <other_name>200 mg Ebselen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0 mg Ebselen oral capsules (SPI-1000), single dose</description>
    <arm_group_label>SPI-1000 Capsule 0 mg Ebselen Placebo</arm_group_label>
    <other_name>0 mg Ebselen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male and female subjects

          -  Within 15% of their ideal weights (Table of &quot;Desirable Weights of Adults,&quot;
             Metropolitan Life Insurance Company, 1983)

          -  Medically healthy subjects with clinically insignificant screening results (laboratory
             profiles, medical histories, ECGs, physical exam);

          -  Voluntarily consented to participate in the study;

          -  Females of childbearing potential were either sexually inactive (abstinent) for 14
             days prior to screening and throughout the study or used one of the following
             acceptable birth control methods: Intrauterine device (IUD) in place for at least 3
             months prior to study; Barrier method (condom or diaphragm) with spermicide for at
             least 14 days prior to screening through study completion; Stable hormonal
             contraceptive for at least 3 months prior to study through completion of study;
             Surgical sterilization (vasectomy) of partner at least 6 months prior to study.
             Females of non-childbearing potential were surgically sterile (bilateral tubal
             ligation with surgery at least 6 months prior to study, hysterectomy, or bilateral
             oophorectomy at least 2 months prior to study).

        Exclusion Criteria:

          -  History or presence of significant cardiovascular, pulmonary, hepatic, renal,
             hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic,
             otologic, or psychiatric disease;

          -  History or presence of alcoholism or drug abuse within the past 2 years;

          -  Hypersensitivity or idiosyncratic reaction to compounds related to ebselen;

          -  Use of any prescription medication within 14 days (with the exception of hormonal
             contraceptives) prior to or during the study;

          -  Use of any over-the-counter medication including vitamins, herbal preparations,
             antacids, cough and cold remedies, etc., within 7 days prior or during the study;

          -  Use of any drugs or substances known to be strong inhibitors or inducers of cytochrome
             P450 enzymes within 28 days prior to dosing;

          -  Abnormal diet (for any reason) during the 30 days prior to dosing;

          -  Donation of whole blood within 56 days prior to the study;

          -  Plasma donation within 7 days prior to the study;

          -  Participation in another clinical trial within 30 days prior to the study;

          -  Female subjects who were pregnant or lactating;

          -  Hemoglobin &lt; 12.0 g/dL;

          -  Orthostatic vital signs which result in: A pulse increase of more than 30 beats per
             minute after 3 minutes standing (compared with semi-recumbent pulse rate); or A pulse
             rate greater than 100 bpm after 3 minutes standing; or A drop in systolic blood
             pressure decrease of at least 20 mm Hg; or A diastolic blood pressure decrease of at
             least 10 mm Hg within 3 minutes of standing (compared with semi-recumbent blood
             pressure).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James C. Kisicki, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma Services</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lynch E, Kil J. Development of Ebselen, a Glutathione Peroxidase Mimic, for the Prevention and Treatment of Noise-Induced Hearing Loss. Semin Hear 2009; 30(1): 047-055</citation>
  </results_reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2011</study_first_submitted>
  <study_first_submitted_qc>October 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2011</study_first_posted>
  <last_update_submitted>June 27, 2016</last_update_submitted>
  <last_update_submitted_qc>June 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebselen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ebselen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

